Charles River Partners with Pluristyx for Stem Cell Research

Charles River enters agreement with Pluristyx to expand its portfolio of human pluripotent stem cells

Overview

Charles River Laboratories International, Inc. announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for the development of cell therapies. The collaboration provides Charles River with broad access to highly characterized and unique stem cell lines, including high-quality embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs) as research tools to support development of new therapeutics.

About Pluristyx & Impact of Agreement

• Pluristyx offers a unique product and technology platform in the stem cell biology field for development of new therapies while reducing timelines and downstream costs. 

• Through the agreement, Charles River will distribute Pluristyx’s wild-type and genetically engineered iPSCs as well as their comprehensive portfolio of normal and disease state ES cell lines. 

• All of Pluristyx’s pluripotent cell lines are produced under full donor consent and the ES cell lines are registered and approved by the US National Institutes of Health (NIH) making them eligible for use in NIH-funded research. 

• Pluristyx’s iPSC panCELLa platform includes the proprietary FailSafe safety-switch technology enabling the development of safer, next-generation cell therapies.

Agreement Terms

• Under the terms of the agreement, Charles River will distribute a broad catalog of Pluristyx’s ES and iPS cell lines for research use and will exclusively offer specific pluripotent stem cell lines derived under Good Tissue Practice to support a path to the clinic. 

• The addition of Pluristyx’s offerings complements Charles River’s expansive portfolio of high-quality human cellular materials.

The Cell lines

• ES and iPS cells provide a valuable tool for researchers to gain access to various types of specialized and differentiated cells that are otherwise inaccessible to study disease onset and progression and to develop a multitude of effective therapies. 

• With its expanded portfolio of ES and iPS cell lines, Charles River enhances its position as a global leader in supplying critical human-derived biomaterials, including a wide range of immune cells and hematopoietic stem cells from both healthy donors and patients to drive advancements in stem cell biology, disease remodelling, toxicity studies, developmental biology, regenerative medicine, drug discovery, and cell therapy development.

Charles River’s Mission

• Charles River is committed to leading the industry in identifying technologies and supporting efforts by global regulatory bodies to advance solutions that reduce the impact on in vivo research models through its 4Rs mission. 

• The development of complex in vitro models using human-derived cells is one of many critical steps in revolutionizing therapeutic research and development. 

• The alliance with Pluristyx provides Charles River clients access to research tools for advancing in vitro translational cell-based assays for drug discovery.

Words from Leaders:-

• CEO: Charles River
“We are thrilled to integrate Pluristyx into our robust portfolio of human cell products and services. This alliance provides our clients with access to high quality research tools, adding considerable value and helping to develop safe and effective therapies to patients across the globe.” - Birgit Girshick, executive vice president and chief operating officer, Charles River.

• CEO: Pluristyx
“We are honoured to work with Charles River as a worldwide distributor of our pluripotent stem cells, including our genetically modified iPSCs that provide an accelerated path to the clinic with development of safer cell therapies. Through this agreement, we can continue our mission to rapidly advance development of next generation therapies,” Benjamin Fryer, PhD, chief executive officer, Pluristyx.

About Pluristyx

Pluristyx, through its panCELLa platform, offers a portfolio of unique iPSC-based technologies, proprietary genetic engineering, and related tool-products and services to provide end-to-end client support throughout the products’ lifecycle.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!